Adagene (ADAG) Other Non-Current Liabilities (2020 - 2026)
Adagene (ADAG) posted quarterly Other Non-Current Liabilities of $205.1 billion for Q4 2025, up 641.16% quarter-over-quarter from $27.7 billion in Q2 2023.
Analysis
Adagene (ADAG) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Adagene (ADAG) has reported Other Non-Current Liabilities for 5 consecutive years, with $205.1 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $205.1 billion; the TTM figure through Dec 2025 stood at $205.1 billion (changed N/A YoY), while the FY2025 annual figure was $205.1 billion, changed N/A from the prior year.
- Other Non-Current Liabilities advanced to $205.1 billion in Q4 2025 per ADAG's latest filing, from $27.7 billion in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $205.1 billion in Q4 2025 and bottomed at $61919.0 in Q2 2021.
- Historically, Other Non-Current Liabilities has averaged $48.6 billion across 4 years, with a median of $28.2 billion in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 48127292.24% — and 2023, when it decreased 7.12%.
- Adagene's Other Non-Current Liabilities stood at $94107.0 in 2021, then jumped by 30516227.16% to $28.7 billion in 2022, then decreased by 3.62% to $27.7 billion in 2023, then jumped by 641.16% to $205.1 billion in 2025.
- Business Quant data shows ADAG's Other Non-Current Liabilities at $205.1 billion in Q4 2025, $27.7 billion in Q2 2023, and $28.7 billion in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Adagene | 213.60 Mn | 213.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Mn |
| Dec 31, 2025 | 205,146.00 |
| Jun 30, 2023 | 27,679.00 |
| Dec 31, 2022 | 28,718.00 |
| Jun 30, 2022 | 29,800.00 |
| Dec 31, 2021 | 94,107.00 |
| Jun 30, 2021 | 61,919.00 |
| Dec 31, 2020 | 91,955.00 |